Published in Breast Care (Basel) on December 11, 2009
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83
Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data. PLoS One (2012) 0.79
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer. Pharmacoeconomics (2016) 0.75
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med (2005) 12.99
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med (1993) 3.03
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol (2007) 2.76
German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health (2008) 2.20
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer (2003) 1.87
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67
Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol (2004) 1.47
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol (2006) 1.47
Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol (1993) 1.24
Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. Med Decis Making (1998) 1.10
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health (2007) 1.06
Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol (1993) 1.02
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int (2004) 0.99
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer (2007) 0.90
Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat (2006) 0.83
Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev (2004) 0.80
German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health (2008) 2.20
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res (2010) 2.17
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res (2010) 1.69
Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review. Pharmacoeconomics (2013) 1.51
Methods for determining cost-benefit ratios for pharmaceuticals in Germany. Eur J Health Econ (2007) 1.49
Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J Rheumatol (2007) 1.46
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol (2011) 1.31
Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum (2005) 1.24
Cataract surgery and the development or progression of age-related macular degeneration: a systematic review. Surv Ophthalmol (2008) 1.09
Effectiveness of nonpharmacological secondary prevention of coronary heart disease. Eur J Cardiovasc Prev Rehabil (2010) 1.06
Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatr (2009) 1.04
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther (2011) 0.96
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol (2010) 0.95
The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev (2012) 0.94
Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ (2014) 0.94
Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required? Arthritis Rheum (2004) 0.93
Medical effectiveness and safety of conventional compared to laparoscopic incisional hernia repair: a systematic review. Surg Endosc (2007) 0.92
Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ (2010) 0.92
The EVIDENT-trial: protocol and rationale of a multicenter randomized controlled trial testing the effectiveness of an online-based psychological intervention. BMC Psychiatry (2013) 0.91
The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis (2014) 0.90
Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess (2010) 0.90
Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals. BMC Neurol (2009) 0.90
Dacron vs. PTFE as bypass materials in peripheral vascular surgery--systematic review and meta-analysis. BMC Surg (2008) 0.90
[Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases]. Herz (2008) 0.89
Measuring economic consequences of preterm birth - Methodological recommendations for the evaluation of personal burden on children and their caregivers. Health Econ Rev (2011) 0.88
Health Technology Assessment of laparoscopic compared to conventional surgery with and without mesh for incisional hernia repair regarding safety, efficacy and cost-effectiveness. GMS Health Technol Assess (2008) 0.87
Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy (2013) 0.86
Treatment costs of attention deficit hyperactivity disorder in Germany. Eur J Health Econ (2012) 0.86
Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings. Rheumatology (Oxford) (2010) 0.86
Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value Health (2003) 0.85
Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards. Eur J Health Econ (2004) 0.85
Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros (2003) 0.84
[Measuring patient satisfaction in integrated healthcare projects--a pilot study with a modified ZAP questionnaire]. Z Evid Fortbild Qual Gesundhwes (2010) 0.83
Therapy of moderate and severe psoriasis. GMS Health Technol Assess (2006) 0.83
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective. Health Econ Rev (2012) 0.82
Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacother (2004) 0.82
Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective. Ann Hematol (2010) 0.81
Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy (2002) 0.81
Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care (2008) 0.81
Evaluation of medical and health economic effectiveness of bariatric surgery (obesity surgery) versus conservative strategies in adult patients with morbid obesity. GMS Health Technol Assess (2008) 0.81
Determinants of willingness to pay for a new therapy in a sample of menopausal-aged women. Pharmacoeconomics (2009) 0.81
Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technol Assess (2009) 0.81
Outpatient medication costs of patients with cystic fibrosis in Germany. Appl Health Econ Health Policy (2010) 0.81
Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. Health Econ Rev (2011) 0.80
A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest (2010) 0.80
Efficacy and cost-effectiveness of the 13C-urea breath test as the primary diagnostic investigation for the detection of Helicobacter pylori infection compared to invasive and non-invasive diagnostic tests. GMS Health Technol Assess (2009) 0.80
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Econ Rev (2014) 0.80
[Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke]. Med Klin (Munich) (2009) 0.80
Therapy of atopic eczema. GMS Health Technol Assess (2006) 0.80
Concepts of care for people with dementia. GMS Health Technol Assess (2009) 0.79
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. Value Health (2009) 0.79
Modeling rheumatoid arthritis using different techniques - a review of model construction and results. Health Econ Rev (2014) 0.79
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. BMC Health Serv Res (2011) 0.79
Regression of liver metastases after treatment with oxaliplatin/capecitabine and development of a progressive multifocal leukoencephalopathy in a patient with advanced thymoma. J Clin Oncol (2013) 0.78
Effects of a Psychological Internet Intervention in the Treatment of Mild to Moderate Depressive Symptoms: Results of the EVIDENT Study, a Randomized Controlled Trial. Psychother Psychosom (2016) 0.78
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ (2005) 0.78
Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrol (2007) 0.78
[Persistence and frequency of prescriptions of subcutaneous allergen-specific immunotherapy (SCIT) prescribed within the German statutory health insurance]. Med Klin (Munich) (2009) 0.78
Influence of tumor necrosis factor α in rheumatoid arthritis. GMS Health Technol Assess (2005) 0.78
Effectiveness and cost-effectiveness of behavioural strategies in the prevention of cigarette smoking. GMS Health Technol Assess (2008) 0.78
Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer. GMS Health Technol Assess (2007) 0.78
Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany. Pediatr Pulmonol (2010) 0.77
Hormones for therapy of climacteric afflictions. GMS Health Technol Assess (2007) 0.77
A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther (2010) 0.77
[Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results]. Med Klin (Munich) (2009) 0.77
Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors. GMS Health Technol Assess (2009) 0.76
Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ (2005) 0.76
Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord (2013) 0.76
Quality of life results of balloon kyphoplasty versus non surgical management for osteoporotic vertebral fractures in Germany. Health Econ Rev (2011) 0.76
[Methodological standards for cost-of-illness studies using breast cancer, prostate cancer and colon cancer as an example]. Z Evid Fortbild Qual Gesundhwes (2009) 0.75
Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches. Expert Rev Pharmacoecon Outcomes Res (2002) 0.75
Behavioural and skill-based early interventions in children with autism spectrum disorders. GMS Health Technol Assess (2009) 0.75
Why is it so difficult to evaluate nursing interventions in dementia? Dement Geriatr Cogn Dis Extra (2012) 0.75
Efficacy and effectiveness of recombinant human activated protein C in severe sepsis of adults. GMS Health Technol Assess (2007) 0.75
Sonographic diagnosis of "acute abdomen" in children and adults. GMS Health Technol Assess (2005) 0.75
Methods of economic evaluation for the German statutory healthcare system. Pharmacoeconomics (2009) 0.75
What effects has the cataract surgery on the development and progression of Age-Related Macular Degeneration (AMD)? GMS Health Technol Assess (2006) 0.75
Bypass materials in vascular surgery. GMS Health Technol Assess (2006) 0.75
Dental indications for the instrumental functional analysis in additional consideration of health-economic aspects. GMS Health Technol Assess (2010) 0.75
Best supportive care from the conservative/non-surgical perspective and its costs in the treatment of patients with advanced medullary thyroid cancer: results of a Delphi panel. Oncol Res Treat (2014) 0.75
[Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists]. Pharm Unserer Zeit (2003) 0.75
[Aspects of outpatient palliative care and assessment of the nursing workload. Survey among care givers in Germany]. Pflege Z (2010) 0.75
Medical and health economic assessment of radiosurgery for the treatment of brain metastasis. GMS Health Technol Assess (2009) 0.75
Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature. Expert Rev Pharmacoecon Outcomes Res (2012) 0.75
Platelet aggregation inhibitors in primary and secondary prevention of ischemic stroke. GMS Health Technol Assess (2006) 0.75